HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Panel pressures FDA for final sunscreen monograph

This article was originally published in The Rose Sheet

Executive Summary

A panel organized by the Citizens for Sun Protection calls for FDA to finalize the long-awaited sunscreen monograph, require sunscreens to provide both UVA and UVB protection and transparent labeling, and approve photostable, broad-spectrum sunscreen ingredients that defend against UVA and UVB rays, before another summer passes, according to Nov. 20 release. FDA issued in August 2007 a proposed rule to amend the OTC Sunscreen Drug Product Monograph by adding a UVA label standard. The rule is stalled in part because the industry views some labeling requirements as unduly burdensome (1"The Rose Sheet" Jan. 14, 2008, p. 3)

You may also be interested in...

Industry Groups Burned About Proposed Sunscreen Labeling Requirements

Sunscreen labeling that claims the product "helps prevent" premature skin aging, cancer and other damage does not suggest that sunscreen alone protects against these conditions, but in fact informs consumers that "complementary measures" are needed for adequate protection, trade groups say

Formycon Chief Sees COVID-19 Boosting Biosimilars

Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.

PDUFA Renewal Negotiations: What Does Industry Want Now?

With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts